Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Coronavirus disease 2019 vaccine administration in patients with reported reactions to polyethylene glycol- and polysorbate-containing therapeutics.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • المؤلفون: Otani, Iris M; Otani, Iris M; Tsao, Lulu R; Tang, Monica
  • المصدر:
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology; vol 129, iss 1, 88-94.e1; 1081-1206
  • نوع التسجيلة:
    Electronic Resource
  • الدخول الالكتروني :
    https://escholarship.org/uc/item/42j9g7h5
    https://escholarship.org/
  • معلومة اضافية
    • Publisher Information:
      eScholarship, University of California 2022-07-01
    • نبذة مختصرة :
      BackgroundPolyethylene glycol (PEG) and polysorbate reactions were initially implicated as a likely risk factor for reacting to coronavirus disease 2019 (COVID-19) vaccines and remain a source of vaccine hesitancy despite increasing evidence that they do not pose an increased risk for COVID-19 vaccine reactions.ObjectiveTo investigate COVID-19 vaccine safety outcomes in patients with reported reactions to PEG- and polysorbate-containing medications and vaccines.MethodsCOVID-19 vaccine safety was reviewed in patients with PEG or polysorbate reactions documented in their electronic medical records at a tertiary academic medical center (cohort 1) and patients referred to Allergy and Immunology with reported PEG or polysorbate reactions (cohort 2). COVID-19 vaccine safety was also reviewed following reported symptoms (onset ≤ 12 hours) to first-dose PEG-containing messenger RNA (mRNA) COVID-19 vaccine (cohort 3).ResultsOf 252 patients in cohort 1 (n = 202) and cohort 2 (n = 50), 236 (94%) received mRNA COVID-19 vaccines (106 Pfizer, 130 Moderna); 235 received both doses. Only 3 patients from cohort 2 developed mild rash following vaccination. None of the 44 patients in cohort 3 with acute symptoms following first-dose mRNA COVID-19 vaccine (27 Pfizer, 17 Moderna) had previously reported PEG or polysorbate reactions. Of these 44 patients, 43 received the second dose and all 3 who developed symptoms following the second dose (1 required epinephrine) had negative PEG skin testing.ConclusionPatients with reported reactions to PEG and polysorbate safely received COVID-19 vaccines. PEG and polysorbate skin testing did not identify patients at risk for first dose or recurrent reactions to COVID-19 vaccines. Screening for PEG and polysorbate allergy may only increase vaccine hesitancy without identifying patients at risk for COVID-19 vaccine reactions.
    • الموضوع:
      Humans; Hypersensitivity; Polyethylene Glycols; Polysorbates; RNA; Messenger; Vaccines; COVID-19; COVID-19 Vaccines; Clinical Research; Immunization; Genetics; Prevention; Vaccine Related; 3.4 Vaccines; Immunology; Allergy; article
    • Availability:
      Open access content. Open access content
      public
    • Note:
      application/pdf
      Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology vol 129, iss 1, 88-94.e1 1081-1206
    • Other Numbers:
      CDLER oai:escholarship.org:ark:/13030/qt42j9g7h5
      qt42j9g7h5
      https://escholarship.org/uc/item/42j9g7h5
      https://escholarship.org/
      1341877826
    • Contributing Source:
      UC MASS DIGITIZATION
      From OAIster®, provided by the OCLC Cooperative.
    • الرقم المعرف:
      edsoai.on1341877826
HoldingsOnline